Table III.

Outcomes of de novo AML patients whose CR sample was analyzed molecularly within a month after CR date according to whether their DNMT3A R882 mutations were cleared at CR or not.

End point	DNMT3A CR Group 1* (n = 12)	DNMT3A CR Group 2* (n = 25)	P	HR (95% CI)
Complete remission, n (%)	12 (100)	25 (100)	–	–
Disease-free survival
Median, years	0·6	0·6	0·84	1·08 (0·49–2·40)
% disease-free at 3 years (95% CI)	25 (6–50)	24 (10–42)
% disease-free at 5 years (95% CI)	25 (6–50)	24 (10–42)
Overall survival
Median, years	1·3	1·5	0·94	1·03 (0·45–2·37)
% alive at 3 years (95% CI)	33 (10–59)	32 (15–50)
% alive at 5 years (95% CI)	33 (10–59)	28 (12–46)

AML, acute myeloid leukaemia; CI, confidence interval; CR, complete remission; HR, hazard ratio; n, number.

^*Group 1 is defined as patients whose DNMT3A R882 mutation cleared below the VAF cut-off of 3% in their remission sample and who had no other AML mutation, and Group 2 is defined as patients with a DNMT3A R882 mutation with a VAF >3% with or without other AML mutations in their remission sample.